ARVN Q4 2025 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-84.0% YoY

Gross Profit

$8M87.4% margin

Operating Income

-$72M-754.7% margin

Net Income

-$67M-709.5% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

-77.3%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$718M

Total Liabilities

$284M

Stockholders' Equity

$434M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$59M	-84.0%
Gross Profit	$8M	$59M	-86.0%
Operating Income	-$72M	-$58M	-23.2%
Net Income	-$67M	-$45M	-49.4%